Cagrilintide is a synthetic peptide that has garnered attention in the field of pharmacology, particularly for its potential applications in metabolic disorders and obesity management. As a modified form of the naturally occurring hormone, it is designed to enhance its therapeutic effects while minimizing side effects. Cagrilintide acts primarily as a GLP-1 (glucagon-like peptide-1) receptor agonist, which plays a crucial role in regulating appetite and glucose metabolism. Its mechanism of action involves stimulating insulin secretion in response to meals, promoting satiety, and reducing food intake. The substance is characterized by its stability and efficacy in clinical settings, making it a candidate for further research and development. Additionally, its chemical structure includes specific amino acid sequences that contribute to its biological activity. As with many peptides, Cagrilintide's pharmacokinetics, including absorption, distribution, metabolism, and excretion, are essential for understanding its therapeutic potential and safety profile. Ongoing studies aim to elucidate its long-term effects and optimal dosing regimens.

Cagrilintide is an amylin-analog, now being developed in combination with the GLP-1 agonist semaglutide to achieve sustained weight loss in persons with overweight and obesity. This drug is an investigational therapy that reduced body weight in a phase 2 trial when administered as monotherapy in participants without diabetes and with a BMI of at least 30 kg/m2 or at least 27 kg/m2 with hypertension or dyslipidaemia[1-2].

Cagrilintide

1415456-99-3: Cagrilintide is a synthetic peptide that has garnered attention in the field of pharmacology, particularly for its potential applications in metabolic disorders and obesity management. As a modified form of the naturally occurring hormone, it is designed to enhance its therapeutic effects while minimizing side effects. Cagrilintide acts primarily as a GLP-1 (glucagon-like peptide-1) receptor agonist, which plays a crucial role in regulating appetite and glucose metabolism. Its mechanism of action involves stimulating insulin secretion in response to meals, promoting satiety, and reducing food intake. The substance is characterized by its stability and efficacy in clinical settings, making it a candidate for further research and development. Additionally, its chemical structure includes specific amino acid sequences that contribute to its biological activity. As with many peptides, Cagrilintide's pharmacokinetics, including absorption, distribution, metabolism, and excretion, are essential for understanding its therapeutic potential and safety profile. Ongoing studies aim to elucidate its long-term effects and optimal dosing regimens.

<p>Cagrilintide: a long-acting amylin analogue, potential obesity treatment, reduces appetite and weight.</p>

<p>Please enquire for more information about Cagrilintide including the price, delivery time and more detailed product information at the technical inquiry form on this page</p>

CAS 1415456-99-3

Cagrilintide

Cagrilintide

Ref: TM-T76262

Cagrilintide

Ref: 3D-BC184537